PMID: 11918070Mar 29, 2002Paper

Enhancement of fibrinolytic activity of U937 cells by malformin A1

The Journal of Antibiotics
Yukio Koizumi, Keiji Hasumi

Abstract

We have found that malformin A1, a cyclopentapeptide metabolite of Aspergillus niger, enhanced 2.0- to 3.2-fold the 125I-fibrin clot lysis when incubated at 1 to approximately 10 microM with both U937 cells and blood plasma, both of which were essential to the malformin A1 action. The effect was inhibited by epsilon-aminocaproic acid and anti-urokinase serum, but not by anti-tissue-type plasminogen activator IgG, showing that the enhancement was mediated by urokinase-catalyzed plasminogen activation. However, malformin A1 affected neither cellular urokinase activity nor cell-free reactions involved in the fibrinolytic pathway. Malformin-treated, washed cell had an increased capacity to degrade fibrin in the presence of plasma. These results suggest that malformin A1 enhances fibrinolytic activity by affecting cell-mediated response to initiate and/or propagate fibrinolytic activity.

Citations

Aug 2, 2007·Biological & Pharmaceutical Bulletin·Keiichi HagimoriHiroshi Tomoda
Dec 10, 2015·Cancer Chemotherapy and Pharmacology·Yongqing LiuHuiqing Yuan
Apr 5, 2018·Scientific Reports·Yukio KoizumiKeiji Kuba
Feb 9, 2019·Chembiochem : a European Journal of Chemical Biology·Yukio KoizumiKeiji Kuba
Jul 26, 2008·The Journal of Antibiotics·Yasuhiro KojimaSatoshi Omura
Sep 2, 2011·Biological & Pharmaceutical Bulletin·Yukio KoizumiKeiji Hasumi
Oct 31, 2009·The Journal of Antibiotics·Yasuhiro KojimaSatoshi Omura
Jan 10, 2009·The Journal of Antibiotics·Yukihiro AsamiHiroyuki Osada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.